Manufacturer of Controlled Substances Notice of Registration, 72976-72977 [2011-30550]

Download as PDF 72976 Federal Register / Vol. 76, No. 228 / Monday, November 28, 2011 / Notices Drug Schedule Noroxymorphone (9668) .............................................................................................................................................................................. The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Alltech Associates, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Alltech Associates Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 18, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. for distribution and sale to its customers. Regarding (9640) the company plans to manufacture another controlled substance for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Chattem Chemicals Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Chattem Chemicals Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. [FR Doc. 2011–30543 Filed 11–25–11; 8:45 am] Dated: November 18, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P II for sale to its customers for formulation into finished pharmaceuticals. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemicals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 18, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–30546 Filed 11–25–11; 8:45 am] [FR Doc. 2011–30549 Filed 11–25–11; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration By Notice dated June 14, 2011, and published in the Federal Register on June 22, 2011, 76 FR 36577, Chattem Chemicals Inc., 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 13, 2011, and published in the Federal Register on June 22, 2011, 76 FR 36577, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805–9372, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Schedule pmangrum on DSK3VPTVN1PROD with NOTICES Drug Gamma Hydroxybutyric Acid (2010). Opium tincture (9630) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Tapentadol (9780) ........................ Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Methadone (9250) ........................ Methadone intermediate (9254) ... II II II II The company plans to manufacture the listed controlled substances in bulk VerDate Mar<15>2010 15:34 Nov 25, 2011 Schedule I Jkt 226001 II II II II II The company plans to manufacture the listed controlled substances in bulk PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 By Notice dated June 22, 2011, and published in the Federal Register on June 29, 2011, 76 FR 38209, Pharmagra Labs Inc., 158 McLean Road, Brevard, North Carolina 28712, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Pentobarbital (2270), a basic class of controlled substance in schedule II. The company plans to manufacture the listed controlled substance for analytical research and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Pharmagra Labs, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Pharmagra Labs, Inc. to ensure that the E:\FR\FM\28NON1.SGM 28NON1 Federal Register / Vol. 76, No. 228 / Monday, November 28, 2011 / Notices company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: November 18, 2011. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2011–30550 Filed 11–25–11; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Federal Bureau of Investigation [OMB Number 1110–0004] Agency Information Collection Activities: Proposed Collection, Comments Requested; Extension of a Currently Approved Collection, Number of Full-time Law Enforcement Employees as of October 31 60-day notice of information collection under review. pmangrum on DSK3VPTVN1PROD with NOTICES ACTION: The Department of Justice, Federal Bureau of Investigation, Criminal Justice Information Services Division (CJIS), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with established review procedures of the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted until January 27, 2012. This process is conducted in accordance with 5 CFR 1320.10. All comments, suggestions, or questions regarding additional information, to include obtaining a copy of the proposed information collection instrument with instructions, should be directed to Mr. Gregory E. Scarbro, Unit Chief, Federal Bureau of Investigation, CJIS Division, Module E–3, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306, or facsimile to (304) 625–3566. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Comments VerDate Mar<15>2010 15:34 Nov 25, 2011 Jkt 226001 should address one or more of the following four points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques of other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection (1) Type of information collection: Extension of a currently approved collection. (2) The title of the form/collection: Number of Full-time Law Enforcement Employees as of October 31 (3) The agency form number, if any, and the applicable component of the department sponsoring the collection: Form Number 1–711, 1–711a, 1–711b; Sponsor: Criminal Justice Information Services Division, Federal Bureau of Investigation, Department of Justice. (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: City, county, state, Federal, and tribal law enforcement agencies. Brief Abstract: This collection is needed to collect information on the number of full-time law enforcement employees, both civilians and officers, throughout the United States. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: There are approximately 18,108 law enforcement agency respondents that submit once a year for a total of 18,108 responses with an estimated response time of 8 minutes per response. (6) An estimate of the total public burden (in hours) associated with this collection: There are approximately 2,414 hours, annual burden, associated with this information collection. If additional information is required contact: Jerri Murray, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 72977 Two Constitution Square, 145 N Street NE., Room 2E–508, Washington, DC 20530. Jerri Murray, Department Clearance Officer, PRA, United States Department of Justice. [FR Doc. 2011–30404 Filed 11–25–11; 8:45 am] BILLING CODE 4410–02–P DEPARTMENT OF LABOR Advisory Committee on Veterans’ Employment, Training and Employer Outreach (ACVETEO): Meeting Veterans’ Employment and Training Service, Labor. ACTION: Notice of open meeting. AGENCY: This notice sets forth the schedule and proposed agenda of a forthcoming meeting of the Advisory Committee on Veterans’ Employment, Training and Employer Outreach (ACVETEO). The ACVETEO will discuss Department of Labor’s Veterans’ Employment and Training Services’ (VETS) core programs and new initiatives regarding efforts that assist veterans seeking employment and raise employer awareness as to the advantages of hiring veterans. There will be an opportunity for persons or organizations to address the committee. Any individual or organization that wishes to do so should contact Mr. Gregory Green (202) 693–4734. Time constraints may limit the number of outside participants/presentations. Individuals who will need accommodations for a disability in order to attend the meeting (i.e., interpreting services, assistive listening devices, and/or materials in alternative format) should notify the Advisory Committee no later than Wednesday, December 7, 2011 by contacting Mr. Gregory Green (202) 693–4734. Requests made after this date will be reviewed, but availability of the requested accommodations cannot be guaranteed. The meeting site is accessible to individuals with disabilities. This notice also describes the functions of the Advisory Committee. Notice of this meeting is required under Section 10(a)(2) of the Federal Advisory Committee Act. This document is intended to notify the general public. Date and Time: Wednesday, December 14, 2011, beginning at 10 a.m. and ending at approximately 4 p.m. (E.S.T.). ADDRESSES: Veterans of Foreign Wars of the United States, 200 Maryland Avenue NE., Washington, DC 20002. ID is required to enter the building. SUMMARY: E:\FR\FM\28NON1.SGM 28NON1

Agencies

[Federal Register Volume 76, Number 228 (Monday, November 28, 2011)]
[Notices]
[Pages 72976-72977]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-30550]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Registration

    By Notice dated June 22, 2011, and published in the Federal 
Register on June 29, 2011, 76 FR 38209, Pharmagra Labs Inc., 158 McLean 
Road, Brevard, North Carolina 28712, made application to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Pentobarbital (2270), a basic class of controlled 
substance in schedule II.
    The company plans to manufacture the listed controlled substance 
for analytical research and clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Pharmagra Labs, Inc. to manufacture the listed basic class of 
controlled substance is consistent with the public interest at this 
time. DEA has investigated Pharmagra Labs, Inc. to ensure that the

[[Page 72977]]

company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance 
with 21 CFR 1301.33, the above named company is granted registration as 
a bulk manufacturer of the basic class of controlled substance listed.

     Dated: November 18, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-30550 Filed 11-25-11; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.